Adverse Events Associated With Aromatase Inhibitors: An Analysis of Real-World Datasets and Drug-Gene Interaction Network

This study analyzed 7,933 adverse event reports related to aromatase inhibitors (AIs) using the FDA Adverse Event Reporting System from 2004 to 2023. It identified 642 positive signals at the preferred term level, highlighting specific adverse events for different AIs. Anastrozole was associated with antiphospholipid syndrome, plantar fasciitis, and autoimmune pancreatitis. Letrozole was linked to androgenetic alopecia, myosclerosis, and pneumonic herpes virus, while exemestane was associated with infection reactivation, decreased thyroxine free, and atrial dilatation. Letrozole had the earliest onset time for adverse events, followed by exemestane and anastrozole. The study underscores the importance of monitoring these adverse events in real-world clinical settings.